valrocemide

Valrocemide is a small molecule anticonvulsant and a derivative of valproic acid and glycinamide. It was developed as a potential treatment for epilepsy, with additional investigation in bipolar disorder and neuropathic pain. Mechanistically, valrocemide acts as an N-valproyl derivative of GABA and glycine; it inhibits human brain myo-inositol-1-phosphate (MIP) synthase activity via apparent competitive inhibition. In preclinical studies, it demonstrated broad-spectrum anticonvulsant activity with low teratogenic potential compared to valproic acid. Valrocemide reached phase II clinical trials for refractory epilepsy but its development was discontinued in 2009[3][4][5][7][8].

Other names

N-ValproylglycinamideN-(2-amino-2-oxoethyl)-2-propylpentanamide